Oral Session 3-7C Hodgkin Lymphoma

[OS3-7C-1] Pembrolizumab for relapsed/refractory Hodgkin lymphoma: 2-year follow-up from Japanese patients

Kazuyuki Shimada¹, Pier L. Zinzani², Akihiro Tomita¹, Kenichi Ishizawa³, Shinichiro Okamoto⁴, Itaru Matsumura⁵, Yoshinobu Maeda⁶, Koji Kato⁷, Akira Wakana⁸, Eunhee Kim⁹, Mohammed Farooqui⁹, Akash Nahar⁹, Takashi Shimamoto⁸, Yasuhiro Koh⁸, Craig H. Moskowitz¹⁰, Takanori Teshima¹¹ (1.Nagoya University, Nagoya, Japan, 2.Institute of Hematology, University of Bologna, Bologna, Italian Republic, 3.Yamagata University, Yamagata, Japan, 4.Keio University, Tokyo, Japan, 5.Kindai University, Osaka, Japan, 6.Okayama University, Okayama, Japan, 7.Kyushu University, Fukuoka, Japan, 8.MSD K.K., Tokyo, Japan, 9.Merck & Co., Inc., Kenilworth, NJ, United States of America, 10.University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, United States of America, 11.Hokkaido University Hospital, Hokkaido, Japan)